Clinical trials: Adult Atopic Dermatitis
Atopic Dermatitis
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07220577
- Testing
- GIA632
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis
- Trial name
- NCT03758716
- Testing
- FB825, FB825-15D11, Anti-CemX
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Fountain Biopharma Inc.
Atopic Dermatitis (AD)
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT07182864
- Testing
- MH004 0.1% Ointment, MH004 0.3% Ointment, MH004 1.0% Ointment
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis.
- Trial name
- ADAIR (NCT05689151)
- Testing
- Abrocitinib
- Where
- 30 sites in France
- Volunteers
- 183 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis of Adults
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis
- Trial name
- NCT07158151
- Testing
- RSS0393 ointment
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis, Skin Diseases
Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
This study aims at evaluating the effect of a topical product on the improvement of quality of life and pain of patients suffering from atopic dermatitis or other skin diseases with dryness or severe xerosis.
- Trial name
- NCT05765461
- Where
- 7 sites in Croatia, Germany and 5 more
- Volunteers
- 4,631 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study of repeated doses of MOR106 administered as IV infusion.
- Trial name
- IGUANA (NCT03568071)
- Testing
- MOR 106
- Where
- 53 sites in Germany, Hungary and 3 more
- Volunteers
- 207 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)
The aim of this trial is to assess the efficacy of LEO 32731 cream 20 mg/g compared with LEO 32731 cream vehicle in adults with mild to moderate AD after 3 weeks of treatment.
- Trial name
- NCT02496546
- Testing
- LEO 32731 cream, LEO 32731 cream vehicle
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD1 (NCT03334396)
- Testing
- Baricitinib
- Where
- 93 sites in Czechia, Denmark and 8 more
- Volunteers
- 660 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
- Trial name
- NCT07173478
- Testing
- OPA-15406, Vehicle
- Where
- Japan
- Volunteers
- 156 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis, Pruritus
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
The purpose of this study is to find out if investigational device, RD047-26, is safe and useful for the treatment of mild to moderate atopic dermatitis.
- Trial name
- NCT01232985
- Testing
- RD047-26
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Oculus Innovative Sciences, Inc.
Atopic Dermatitis
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD.
- Trial name
- NCT05571943
- Testing
- Difamilast
- Where
- 63 sites in United States
- Volunteers
- 542 people
- Sponsor
- Acrotech Biopharma Inc.
Moderate to Severe Atopic Dermatitis
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of SHR-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously…
- Trial name
- NCT06012812
- Testing
- SHR-1819 injection
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in adult subjects with atopic dermatitis
- Trial name
- NCT01702181
- Testing
- OPA-15406, Tacrolimus
- Where
- 12 sites in United States
- Volunteers
- 92 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild to Moderate Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients
This study aims to evaluate the efficacy and safety of IN-115314 Ointment in mild to moderate atopic dermatitis adult patients
- Trial name
- NCT07073677
- Testing
- IN-115314 Ointment 1%, IN-115314 Ointment 3%
- Where
- South Korea
- Volunteers
- 162 people
- Sponsor
- HK inno.N Corporation
Dermatitis, Atopic
A Study Assessing GW870086's Potential to Cause Skin Thinning
This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to explore the potential for skin thinning in healthy adult volunteers after 42±2 days of treatment.
- Trial name
- NCT01381445
- Testing
- GW870086 0.2%, GW870086 2%, Clobetasol Propionate
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06585202
- Testing
- ATI-2138
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
- Trial name
- NCT05717920
- Testing
- ADX-629 (Open-label)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Aldeyra Therapeutics, Inc.